See how top analysts and institutions rate OSCR — including buy, hold, and sell recommendations.
| Rating Source | Action | Rating | Target Price | Updated |
|---|---|---|---|---|
| Goldman | Initiated | Neutral | $17 | 2025-10-14 |
| Robert W. Baird | Downgrade | Outperform → Neutral | $14 | 2025-07-25 |
| UBS | Downgrade | Neutral → Sell | $11 | 2025-07-15 |
| Piper Sandler | Downgrade | Overweight → Neutral | $14 | 2025-07-14 |
| Wells Fargo | Downgrade | Equal Weight → Underweight | $10 | 2025-07-11 |
| Barclays | Initiated | Underweight | $17 | 2025-07-02 |
| Raymond James | Downgrade | Outperform → Mkt Perform | 2025-06-24 |
| Date | Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|---|
| November 2025 | 0 | 0 | 4 | 3 | 2 |
| October 2025 | 0 | 0 | 3 | 3 | 2 |
| September 2025 | 0 | 0 | 3 | 3 | 2 |
| July 2025 | 0 | 1 | 2 | 3 | 2 |
The majority of institutional investors have issued a "Buy" rating for OSCR, and analyst sentiment aligns closely, with very few "Sell" recommendations. This suggests a broadly favorable outlook for the stock's performance.
